| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 7.832 | 10.133 | 10.707 | 10.223 | 10.688 | 13.671 | 14.550 | 12.745 | 19.744 | 21.078 |
| Total Income - EUR | 7.832 | 10.133 | 11.801 | 10.223 | 10.688 | 13.671 | 14.550 | 12.745 | 19.744 | 21.078 |
| Total Expenses - EUR | 2.330 | 4.076 | 4.727 | 3.735 | 7.274 | 7.822 | 8.899 | 4.340 | 7.913 | 14.447 |
| Gross Profit/Loss - EUR | 5.503 | 6.057 | 7.074 | 6.488 | 3.414 | 5.849 | 5.651 | 8.405 | 11.831 | 6.631 |
| Net Profit/Loss - EUR | 5.268 | 5.760 | 6.723 | 6.181 | 3.094 | 5.414 | 5.214 | 8.087 | 10.201 | 5.529 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Hipocrat Bio S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 13.374 | 12.851 | 12.253 | 11.655 | 11.063 | 10.525 | 10.052 | 10.002 | 9.511 | 9.944 |
| Current Assets | 540 | 991 | 7.706 | 11.538 | 10.109 | 11.367 | 14.409 | 20.239 | 16.008 | 8.516 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 126 | 124 | 122 | 120 | 118 | 116 | 113 | 175 | 6.275 | 2.346 |
| Cash | 415 | 866 | 7.583 | 11.418 | 9.991 | 11.252 | 14.296 | 20.064 | 9.733 | 6.170 |
| Shareholders Funds | 7.001 | 12.689 | 19.197 | 22.877 | 21.091 | 21.753 | 24.357 | 28.923 | 21.786 | 16.985 |
| Social Capital | 47 | 47 | 46 | 45 | 44 | 43 | 42 | 43 | 42 | 42 |
| Debts | 6.914 | 1.153 | 762 | 316 | 81 | 139 | 104 | 1.318 | 3.734 | 1.474 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6820 - 6820" | |||||||||
| CAEN Financial Year |
6820
|
|||||||||
Comments - Hipocrat Bio S.r.l.